CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets.

英国剑桥--（商业新闻短讯）--专业临床前合同研究组织（CRO）和离子通道筛查领导者Metrion Biosciences（“Metrion”）今天宣布任命Lee Patterson为其新任CEO，自2024年12月2日起生效。作为一名经验丰富的生命科学和首席风险官，Lee将指导该公司实施雄心勃勃的增长战略，加强其专业服务，并在关键的全球市场进一步扩张。

He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post..

他接替安德鲁·索桑（AndrewSouthan）博士，安德鲁·索桑（AndrewSouthan）博士在任职五年后决定辞去首席执行官一职。。

A renowned leader in the sector, Lee Patterson specializes in steering preclinical CROs to implement robust and effective plans for long-term commercial growth. Previously CEO at Charnwood Discovery, a provider of integrated drug discovery services with a global biotech and pharma client base, he led the company through its successful acquisition by Concept Life Sciences in October 2024.

Lee Patterson是该领域的知名领导者，他专门指导临床前CRO实施稳健有效的长期商业增长计划。曾任Charnwood Discovery首席执行官，该公司是一家综合药物发现服务提供商，拥有全球生物技术和制药客户群，他领导该公司于2024年10月成功收购了Concept Life Sciences。

Prior to this, Lee served as Chief Operating Officer at Quanticate, a global biometrics CRO, and Chief Operating Officer at Concept Life Sciences. He also held several executive roles at Covance/Labcorp, the most recent being Executive Director, Global Operations and Early Development Management Office..

在此之前，Lee曾担任Quanticate的首席运营官，Quanticate是一家全球生物识别首席运营官，Concept Life Sciences的首席运营官。他还曾在Covance/Labcorp担任多个执行职务，最近担任全球运营和早期发展管理办公室执行董事。。

Lee will join recently appointed CCO Dr Chris Mathes as the latest addition to Metrion’s senior leadership team1. Working closely alongside Chris and the broader management team, Lee’s C-suite level expertise and experience will support Metrion to bolster its global commercial presence and scientific capabilities..

。与Chris和更广泛的管理团队密切合作，Lee的C-suite级专业知识和经验将支持Metrion加强其全球商业存在和科学能力。。

Outgoing CEO Dr Andrew Southan has led Metrion successfully since 2019, more than doubling revenues over that time and overseeing the Company’s growth in staffing, laboratory facilities and international client base. He also led the Company’s successful £3.7M equity financing round in December 2023..

即将离任的首席执行官安德鲁·索桑博士自2019年以来成功领导了Metrion，在此期间收入翻了一番多，并监督了该公司在人员配备、实验室设施和国际客户群方面的增长。2023年12月，他还领导了该公司成功的370万英镑股权融资回合。。

“On behalf of the Board and management team, I would like to thank Andy Southan for his dedicated leadership over the last five years, in particular establishing Metrion’s reputation as a high quality, specialist CRO and a leading centre of expertise in ion channel biology,” said Keith McCullagh, Chairman, Metrion Biosciences.

Metrion Biosciences董事长Keith McCullagh表示：“我谨代表董事会和管理团队，感谢安迪·索桑（Andy Southan）在过去五年中的敬业领导，特别是确立了Metrion作为高质量专业CRO和离子通道生物学领先专业中心的声誉。”。

“At the same time, I am delighted to welcome Lee Patterson to the Company. His experience of leading commercial CROs and his expertise in enhancing operational efficiencies are both outstanding and we look forward to working with him to continue Metrion’s growth as a specialist CRO serving global markets.”.

“同时，我很高兴欢迎Lee Patterson来到公司。他领导商业CRO的经验和他在提高运营效率方面的专业知识都很出色，我们期待着与他合作，继续Metrion作为服务全球市场的专业CRO的发展。”。

Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has built an impressive reputation in ion channel drug discovery, with proven commitment to outstanding customer service and world class science. I am excited to join this talented team and look forward to working with them to enhance and expand our specialised services to meet the needs of our clients worldwide.”.

Metrion Biosciences首席执行官Lee Patterson评论道：“Metrion Biosciences在离子通道药物发现方面建立了令人印象深刻的声誉，并致力于卓越的客户服务和世界一流的科学。我很高兴加入这个才华横溢的团队，并期待着与他们合作，增强和扩大我们的专业服务，以满足我们全球客户的需求。”。

Press Release (23rd July, 2024): Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

新闻稿（2024年7月23日）：Metrion Biosciences任命Chris Mathes博士为首席商务官